In a series of significant developments for Argenx, the therapeutics group has secured second US approval for its Vyvgart Hytrulo as treatment for chronic inflammatory demyelinating neuropathy (CIDP). The FDA has greenlighted this solution that targets auto-immune diseases. Despite a challenge thrown by Johnson & Johnson with positive Phase III data, Argenx's market offering has seen an overall upward spiral with approval for Vyvgart creating ripples in the industry. Even as multi-national operative J&J prepares to enter the field, Argenx is making strides in the biotech market with Vyvgart poised for possible expansion. Notably, however, Argenx decided to stop the clinical development of efgartigimod for AAV. Despite this, the company has been getting ready for the launch of Vyvgart in its next potential indication. In some unfortunate developments, Argenx's Vyvgart trials fell short of the placebo effect and faced a setback in the autoimmune disorder front. Nonetheless, Argenx remains a strong contender in the market with a high potential for outperformance in 2025.
argenx News Analytics from Wed, 01 Nov 2023 07:00:00 GMT to Sun, 07 Jul 2024 11:03:45 GMT -
Rating 7
- Innovation 4
- Information 5
- Rumor -1
